GLP1R and diabetic kidney disease: Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce atherosclerotic major adverse cardiovascular (CVs) events to a similar degree in patients with established atherosclerotic CV disease, whereas SGLT2i have a more marked effect on preventing hospitalization for heart failure and progression of DKD [14, 15].